BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 21111980)

  • 1. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial.
    Giamouzis G; Butler J; Starling RC; Karayannis G; Nastas J; Parisis C; Rovithis D; Economou D; Savvatis K; Kirlidis T; Tsaknakis T; Skoularigis J; Westermann D; Tschöpe C; Triposkiadis F
    J Card Fail; 2010 Dec; 16(12):922-30. PubMed ID: 21111980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial.
    Triposkiadis FK; Butler J; Karayannis G; Starling RC; Filippatos G; Wolski K; Parissis J; Parisis C; Rovithis D; Koutrakis K; Skoularigis J; Antoniou CK; Chrysohoou C; Pitsavos C; Stefanadis C; Nastas J; Tsaknakis T; Mantziari L; Giannakoulas G; Karvounis H; Kalogeropoulos AP; Giamouzis G
    Int J Cardiol; 2014 Mar; 172(1):115-21. PubMed ID: 24485633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety.
    Ng TM; Hshieh S; Chan CY; Elkayam U
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):373-81. PubMed ID: 22610091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
    Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A
    Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure.
    Thomson MR; Nappi JM; Dunn SP; Hollis IB; Rodgers JE; Van Bakel AB
    J Card Fail; 2010 Mar; 16(3):188-93. PubMed ID: 20206891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial.
    Sharma K; Vaishnav J; Kalathiya R; Hu JR; Miller J; Shah N; Hill T; Sharp M; Tsao A; Alexander KM; Gupta R; Montemayor K; Kovell L; Chasler JE; Lee YJ; Fine DM; Kass DA; Weiss RG; Thiemann DR; Ndumele CE; Schulman SP; Russell SD;
    JACC Heart Fail; 2018 Oct; 6(10):859-870. PubMed ID: 30098962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
    Mahesh B; Yim B; Robson D; Pillai R; Ratnatunga C; Pigott D
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):370-6. PubMed ID: 18243724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.
    Rogers HL; Marshall J; Bock J; Dowling TC; Feller E; Robinson S; Gottlieb SS
    J Card Fail; 2008 Feb; 14(1):1-5. PubMed ID: 18226766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nesiritide on renal function in patients admitted for decompensated heart failure.
    Arora S; Clarke K; Srinivasan V; Gradman A
    QJM; 2007 Nov; 100(11):699-706. PubMed ID: 17971392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study.
    Paterna S; Di Pasquale P; Parrinello G; Fornaciari E; Di Gaudio F; Fasullo S; Giammanco M; Sarullo FM; Licata G
    J Am Coll Cardiol; 2005 Jun; 45(12):1997-2003. PubMed ID: 15963399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients.
    Chow SL; Peng JT; Okamoto MP; Heywood JT
    Ann Pharmacother; 2007 Apr; 41(4):556-61. PubMed ID: 17389662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
    Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion of furosemide combined with low-dose dopamine compared to intermittent boluses in acutely decompensated heart failure is less nephrotoxic and carries a lower readmission at thirty days.
    Aziz EF; Alviar CL; Herzog E; Cordova JP; Bastawrose JH; Pamidimukala CK; Tojino A; Park TS; Musat D; Kukin M
    Hellenic J Cardiol; 2011; 52(3):227-35. PubMed ID: 21642071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal effects of added low-dose dopamine in acute heart failure patients with diuretic resistance to natriuretic peptide.
    Kamiya M; Sato N; Nozaki A; Akiya M; Okazaki H; Takahashi Y; Mizuno K; Shimizu W
    J Cardiovasc Pharmacol; 2015 Mar; 65(3):282-8. PubMed ID: 25748698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troponin I release after intravenous treatment with high furosemide doses plus hypertonic saline solution in decompensated heart failure trial (Tra-HSS-Fur).
    Parrinello G; Di Pasquale P; Torres D; Cardillo M; Schimmenti C; Lupo U; Iatrino R; Petrantoni R; Montaina C; Giambanco S; Paterna S
    Am Heart J; 2012 Sep; 164(3):351-7. PubMed ID: 22980301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.